Preclinical characterization of a novel STING agonist, MK-1454

被引：0

作者：

Cemerski, Saso ^{[1
]}

Altman, Michael ^{[1
]}

Bandi, Madhavi ^{[1
]}

Chang, Wonsuk ^{[2
]}

Chen, Yiping ^{[1
]}

Cui, Long ^{[1
]}

Cumming, Jared ^{[1
]}

Dorosh, Lauren ^{[1
]}

Flateland, Lauren ^{[1
]}

Ma, Yanhong ^{[1
]}

Javaid, Sarah ^{[1
]}

Ho, Thu ^{[3
]}

Kopinja, Johnny ^{[1
]}

Laskey, Jason ^{[1
]}

Minnihan, Ellen ^{[1
]}

Price, Laura ^{[3
]}

Mogg, Robin ^{[3
]}

O'Donnell, Gregory ^{[3
]}

Pan, Bo-Sheng ^{[1
]}

Perera, Samanthi ^{[1
]}

Piesvaux, Jennifer ^{[1
]}

Presland, Jeremy ^{[1
]}

Rakhilina, Larissa ^{[1
]}

Schroeder, Gottfried ^{[1
]}

Slavonic, Michael ^{[1
]}

Smock, Steven ^{[1
]}

Trotter, Benjamin Wesley ^{[1
]}

Wyss, Daniel ^{[2
]}

Zhao, Qing ^{[4
]}

Zhao, Shuxia ^{[1
]}

Sadekova, Svetlana ^{[5
]}

Yu, Ying ^{[5
]}

Khilnani, Anuradha ^{[4
]}

Tse, Archie ^{[4
]}

机构：

[1] Merck Res Labs, Boston, MA USA

[2] Merck Res Labs, Kenilworth, NJ USA

[3] Merck Res Labs, West Point, PA USA

[4] Merck Res Labs, Rahway, NJ USA

[5] Merck Res Labs, Palo Alto, CA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O31

引用

页数：2

共 50 条

[1] Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer
Chang, Wonsuk
Altman, Michael D.
Lesburg, Charles A.
Perera, Samanthi A.
Piesvaux, Jennifer A.
Schroeder, Gottfried K.
Wyss, Daniel F.
Cemerski, Saso
Chen, Yiping
DiNunzio, Edward
Haidle, Andrew M.
Ho, Thu
Kariv, Ilona
Knemeyer, Ian
Kopinja, Johnny E.
Lacey, Brian M.
Laskey, Jason
Lim, Jongwon
Long, Brian J.
Ma, Yanhong
Maddess, Matthew L.
Pan, Bo-Sheng
Presland, Jeremy P.
Spooner, Edward
Steinhuebel, Dietrich
Quang Truong
Zhang, Zhibo
Fu, Jianmin
Addona, George H.
Northrup, Alan B.
Parmee, Emma
Tata, James R.
Bennett, David Jonathan
Cumming, Jared N.
Siu, Tony
Trotter, B. Wesley
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (07) : 5675 - 5689
[2] Diverse Catalytic Reactions for the Stereoselective Synthesis ofCyclic Dinucleotide MK-1454
Benkovics, Tamas
Peng, Feng
Phillips, Eric M.
An, Chihui
Bade, Rachel S.
Chung, Cheol K.
Dance, Zachary E. X.
Fier, Patrick S.
Forstater, Jacob H.
Liu, Zhijian
Liu, Zhuqing
Maligres, Peter E.
Marshall, Nicholas M.
Marzijarani, Nastaran Salehi
McIntosh, John A.
Miller, Steven P.
Moore, Jeffrey C.
Neel, Andrew J.
Obligacion, Jennifer, V
Pan, Weilan
Pirnot, Michael T.
Poirier, Marc
Reibarkh, Mikhail
Sherry, Benjamin D.
Song, Zhiguo Jake
Tan, Lushi
Turnbull, Ben W. H.
Verma, Deeptak
Waldman, Jacob H.
Wang, Lu
Wang, Tao
Winston, Matthew S.
Xu, Feng
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2022, 144 (13) : 5855 - 5863
[3] Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
Harrington, K. J.
Brody, J.
Ingham, M.
Strauss, J.
Cemerski, S.
Wang, M.
Tse, A.
Khilnani, A.
Marabelle, A.
Golan, T.
ANNALS OF ONCOLOGY, 2018, 29 : 712 - 712
[4] Preclinical characterization of a dual PPARα/γ Agonist-MK-767
Doebber, T
Berger, J
Zhou, GC
Kelly, L
Meurer, R
Chao, YS
Cai, T
Wright, S
Moller, D
DIABETES, 2003, 52 : A117 - A117
[5] Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity
Yang, Jingsong
Adam, Michael
Clemens, Jim
Creech, Katrina
Schneck, Jess
Pasikanti, Kishore
Jean-Luc Tran
Joglekar, Devika
Hopson, Chris
Pesiridis, Scott
Ramanjulu, Joshi
Lian, Yiqian
Adams, Jerry L.
Smothers, James
Hoos, Axel
CANCER RESEARCH, 2018, 78 (13)
[6] Preclinical characterization of ALG-031048, a novel STING agonist with potent anti-tumor activity in mice
Jekle, Andreas
Thatikonda, Santosh
Stevens, Sarah
Williams, Caroline
Kinkade, April
Ren, Suping
Jaisinghani, Ruchika
Zhang, Qingling
Misner, Dinah
Stoycheva, Antitsa
Deval, Jerome
Mukherjee, Sucheta
Gonzalvez, Francois
Chanda, Sushmita
Smith, David B.
Symons, Julian A.
Blatt, Lawrence M.
Beigelman, Leonid
CANCER RESEARCH, 2020, 80 (16)
[7] Preclinical studies of SB 11285, a novel STING agonist for immuno-oncology.
Challa, Sreerupa Valli
Zhou, Shenghua
Sheri, Anjaneyulu
Padmanabhan, Seetharamaiyer
Meher, Geeta
Gimi, Rayomand
Schmidt, Diane
Cleary, Dillon
Afdhal, Nezam
Iyer, Radhakrishnan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] Preclinical characterization of a novel non-cyclic dinucleotide small molecule STING agonist with potent antitumor activity in mice
Wang, Zezhou
Dove, Peter
Rosa, David
Bossen, Bolette
Helke, Simone
Charbonneau, Marilyse
Brinen, Laura
Dodge, Karen
Lin, Gloria H.
Galligan, Carole
Viller, Natasja N.
Wong, Mark
Lee, Vivian
Catalano, Tina
Uger, Robert A.
Slassi, Malik
Winston, Jeff
CANCER RESEARCH, 2019, 79 (13)
[9] Enhancing immunotherapy of STING agonist for lymphoma in preclinical models
Sallets, Adrienne
Robinson, Sophie
Kardosh, Adel
Levy, Ronald
BLOOD ADVANCES, 2018, 2 (17) : 2230 - 2241
[10] Radiosynthesis and preclinical biodistribution of a carbon-11-labelled STING agonist
Hill, James
Schreurs, Maxime
Faber, Gerjanne
Mooijer, Martinus
Kooijman, Esther
Verlaan, Mariska
Bonasera, Thomas
Cleveland, Matthew
Parker, Christine
Galette, Paul
Vugts, Danielle
Bergstrom, Mats
Beaino, Wissam
Windhorst, Albert
NUCLEAR MEDICINE AND BIOLOGY, 2022, 108 : S193 - S193

← 1 2 3 4 5 →